| Q64116052 | 2018 in review: five hot topics in tropical medicine |
| Q48015887 | A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria |
| Q37617688 | A retrospective analysis of the protective efficacy of tafenoquine and mefloquine as prophylactic anti-malarials in non-immune individuals during deployment to a malaria-endemic area. |
| Q36807333 | Adherence to malaria prophylaxis among Peace Corps Volunteers in the Africa region, 2013 |
| Q36446343 | Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study |
| Q36806815 | Antimalarial and antimicrobial activities of 8-Aminoquinoline-Uracils metal complexes |
| Q34456807 | Antimalarial compounds in Phase II clinical development. |
| Q62125563 | Approval of Tafenoquine for Malaria Chemoprophylaxis |
| Q37707806 | Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections |
| Q33664324 | Chemoprophylaxis of Tropical Infectious Diseases. |
| Q64056980 | Clinical utility of tafenoquine in the prevention of relapse of malaria: a review on the mode of action and emerging trial data |
| Q35746028 | Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics |
| Q38027179 | Emerging drugs for malaria |
| Q33916111 | Expanding the Antimalarial Drug Arsenal-Now, But How? |
| Q33892018 | Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine |
| Q33908425 | Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs. |
| Q35876668 | Intravenous artesunate for severe malaria in travelers, Europe |
| Q37643622 | KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro |
| Q34673443 | Malaria Chemoprophylaxis and Self-Reported Impact on Ability to Work: Mefloquine Versus Doxycycline |
| Q26770267 | Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force |
| Q55506601 | Malaria Prophylaxis: A Comprehensive Review. |
| Q58214241 | Malaria and Travellers |
| Q42338471 | Management of Plasmodium vivax risk and illness in travelers |
| Q47140318 | Mefloquine for preventing malaria during travel to endemic areas |
| Q90310182 | Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review |
| Q37353434 | Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects |
| Q38129536 | Plasmodium falciparum gametocytes: with a view to a kill. |
| Q24202900 | Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine |
| Q26471722 | Primaquine or tafenoquine for preventing malaria in people travelling to or living in endemic areas |
| Q94315821 | Primaquine or tafenoquine for preventing malaria in people travelling to or living in endemic areas |
| Q37219164 | Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine |
| Q26743363 | Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives |
| Q92674900 | Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers |
| Q38379720 | Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria |
| Q36444170 | Reinventing primaquine for endemic malaria |
| Q39253978 | Single dose treatment of malaria - current status and perspectives |
| Q36324967 | Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries |
| Q26741307 | Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date |
| Q58607952 | Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines |
| Q34811224 | Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects |
| Q24186356 | Tafenoquine for preventing relapse in people with Plasmodium vivax malaria |
| Q58089503 | Tafenoquine for travelers' malaria: evidence, rationale and recommendations |
| Q34393524 | Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study |
| Q92297877 | Tafenoquine succinate for malaria prevention |
| Q38774112 | The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). |
| Q30666192 | The challenges of introducing routine G6PD testing into radical cure: a workshop report |